InterPAD - DETAILS

Ertugliflozin, 1210344-57-2, PF-04971729, Steglatro, PF04971729, PF 04971729, MK-8835, (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, UNII-6C282481IP, (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, PF-04971729-00, 6C282481IP, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose, CHEMBL1770248, PF 04971729-00, (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol, 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol, beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-, (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, beta-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-, Ertugliflozin [USAN:INN], ertugliflozina, ertugliflozine, ertugliflozinum, (1S,2S,3S,4R,5S)-5-(4-CHLORO-3-((4-ETHOXYPHENYL)METHYL)PHENYL)-1-(HYDROXYMETHYL)-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL, (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; MK 8835; PF 04971729; PF 04971729-00; Steglatro, ERTUGLIFLOZIN [MI], ERTUGLIFLOZIN [INN], Ertugliflozin (USAN/INN), ERTUGLIFLOZIN [USAN], SCHEMBL181047, ERTUGLIFLOZIN [WHO-DD], GTPL8376, PF-04971729;Ertugliflozin, A10BK04, DTXSID40153120, EX-A407, CHEBI:188719, MCIACXAZCBVDEE-CUUWFGFTSA-N, ERTUGLIFLOZIN [ORANGE BOOK], AMY32613, BDBM50342885, MFCD21609259, s5413, AKOS025404928, STELUJAN COMPONENT ERTUGLIFLOZIN, CCG-269087, CS-0976, DB11827, SEGLUROMET COMPONENT ERTUGLIFLOZIN, AC-29007, AS-35204, ERTUGLIFLOZIN COMPONENT OF STELUJAN, HY-15461, ERTUGLIFLOZIN COMPONENT OF SEGLUROMET, NS00072894, D10313, EN300-7393259, J-504029, Q27077223, (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol, (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol

Name	Ertugliflozin
PubChem CID	44814423
Molecular Weight	436.9g/mol
Synonyms	Ertugliflozin, 1210344-57-2, PF-04971729, Steglatro, PF04971729, PF 04971729, MK-8835, (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, UNII-6C282481IP, (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, PF-04971729-00, 6C282481IP, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose, CHEMBL1770248, PF 04971729-00, (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol, 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol, beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-, (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, beta-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-, Ertugliflozin [USAN:INN], ertugliflozina, ertugliflozine, ertugliflozinum, (1S,2S,3S,4R,5S)-5-(4-CHLORO-3-((4-ETHOXYPHENYL)METHYL)PHENYL)-1-(HYDROXYMETHYL)-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL, (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; MK 8835; PF 04971729; PF 04971729-00; Steglatro, ERTUGLIFLOZIN [MI], ERTUGLIFLOZIN [INN], Ertugliflozin (USAN/INN), ERTUGLIFLOZIN [USAN], SCHEMBL181047, ERTUGLIFLOZIN [WHO-DD], GTPL8376, PF-04971729;Ertugliflozin, A10BK04, DTXSID40153120, EX-A407, CHEBI:188719, MCIACXAZCBVDEE-CUUWFGFTSA-N, ERTUGLIFLOZIN [ORANGE BOOK], AMY32613, BDBM50342885, MFCD21609259, s5413, AKOS025404928, STELUJAN COMPONENT ERTUGLIFLOZIN, CCG-269087, CS-0976, DB11827, SEGLUROMET COMPONENT ERTUGLIFLOZIN, AC-29007, AS-35204, ERTUGLIFLOZIN COMPONENT OF STELUJAN, HY-15461, ERTUGLIFLOZIN COMPONENT OF SEGLUROMET, NS00072894, D10313, EN300-7393259, J-504029, Q27077223, (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol, (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol
Drug Type	Small molecule
Formula	C₂₂H₂₅ClO₇
SMILES	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl
InChI	1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
InChIKey	MCIACXAZCBVDEE-CUUWFGFTSA-N
CAS Number	1210344-57-2
ChEMBL ID	CHEMBL1770248
ChEBI ID	CHEBI:188719
TTD ID	D0Q3VE
Drug Bank ID	DB11827
KEGG ID	D10313
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Ertugliflozin
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.